

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Fairmount Funds Management LLC</u> (Last) (First) (Middle) 200 BARR HARBOR DRIVE SUITE 400 (Street) WEST CONSHOHOCKEN PA 19428 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Oruka Therapeutics, Inc. [ORKA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/02/2026	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$55.23	06/02/2026		A		9,136		(I)	06/01/2036	Common Stock	9,136	\$0	9,136	I(2)	By: Peter Harwin

1. Name and Address of Reporting Person*
Fairmount Funds Management LLC
 (Last) (First) (Middle)
 200 BARR HARBOR DRIVE
 SUITE 400
 (Street)
 WEST CONSHOHOCKEN PA 19428
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Fairmount Healthcare Fund II L.P.
 (Last) (First) (Middle)
 200 BARR HARBOR DRIVE
 SUITE 400
 (Street)
 WEST CONSHOHOCKEN PA 19428
 (City) (State) (Zip)

1. Name and Address of Reporting Person*		
Fairmount Healthcare Co-Invest III L.P.		
(Last)	(First)	(Middle)
200 BARR HARBOR DRIVE SUITE 400		
(Street)		
WEST CONSHOHOCKEN PA		19428
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Harwin Peter Evan		
(Last)	(First)	(Middle)
200 BARR HARBOR DRIVE SUITE 400		
(Street)		
WEST CONSHOHOCKEN PA		19428
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Kiselak Tomas		
(Last)	(First)	(Middle)
200 BARR HARBOR DRIVE SUITE 400		
(Street)		
WEST CONSHOHOCKEN PA		19428
(City)	(State)	(Zip)

Explanation of Responses:

1. This option represents a right to purchase 9,136 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2026, subject to the recipient's continued service to the Issuer.
 2. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest III L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Fairmount, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest III L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.

/s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC	06/03/2026
/s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II L.P.	06/03/2026
/s/ Peter Harwin, Managing Member of Fairmount Healthcare Co-Invest III L.P.	06/03/2026
/s/ Peter Harwin	06/03/2026
/s/ Tomas Kiselak	06/03/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.